Tag: Skolkovo

New investments in the innovative biotechnology company “Target Medicals”

RDIF, AstraZeneca and Unicorn Capital Partners invest in Target Medicals, developing aldosterone synthase inhibitor for the treatment of resistant...

The Skolkovo Innovation Center has completed Phase I of a clinical trial for stomach cancer treatment

Alofanib helped to stop the development of the disease in 70% of patients. Such data were obtained during a...